Compare MAT & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAT | IMVT |
|---|---|---|
| Founded | 1945 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 5.0B |
| IPO Year | 1994 | 2019 |
| Metric | MAT | IMVT |
|---|---|---|
| Price | $15.76 | $24.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 9 |
| Target Price | $20.90 | ★ $30.78 |
| AVG Volume (30 Days) | ★ 4.9M | 896.5K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.24 | N/A |
| Revenue | ★ $5,347,623,000.00 | N/A |
| Revenue This Year | $5.99 | N/A |
| Revenue Next Year | $5.05 | N/A |
| P/E Ratio | $12.97 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.95 | $12.72 |
| 52 Week High | $22.48 | $29.25 |
| Indicator | MAT | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 32.49 | 40.52 |
| Support Level | $15.41 | $24.63 |
| Resistance Level | $19.33 | $27.71 |
| Average True Range (ATR) | 0.49 | 1.17 |
| MACD | 0.09 | -0.30 |
| Stochastic Oscillator | 18.96 | 15.90 |
Mattel manufactures and markets toy products that are sold to its wholesale partners and direct to retail customers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, hand-held and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Nearly 60% of its net sales were generated from North America in 2025, with the remainder stemming from international markets.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.